RecruitingNCT06952426

A Mobile App-Based Study to Evaluate Disease Burden and Treatment Patterns in Immunoglobulin A Nephropathy (IgAN) in the US

A Mobile App-Based, Prospective, Observational Study to Evaluate Disease Burden and Treatment Patterns in Immunoglobulin A Nephropathy (IgAN) in the US

Sponsor

Novartis Pharmaceuticals

Enrollment

300 participants

Start Date

Mar 4, 2025

Study Type

OBSERVATIONAL

Conditions

Immunoglobulin A Nephropathy

Summary

The study aims to longitudinally capture the full spectrum of symptoms, treatment utilization, and overall health-related quality of life (HRQoL) experienced by Immunoglobulin A nephropathy (IgAN) patients and their caregivers.

Eligibility

Min Age: 18 Years

Inclusion Criteria3

Diagnosis of IgAN, regardless of symptom or treatment history
Adult aged 18 or older; adult caregiver to an adult patient aged 18 or older; or adult caregiver to a pediatric patient under 18 years of age
US-based with a proficient understanding of and ability to read the English language

Exclusion Criteria1

None

Print for Your Doctor

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

OTHERNo intervention

Participants and their caregivers will report home reported outcomes (HRO) data on symptom burden to understand symptom variability and health-related quality of life (HRQoL).

OTHEROther treatment

Participants and their caregivers will report HRO data on symptom burden and treatment usage to understand symptom variability and HRQoL.

OTHERIptacopan

Participants and their caregivers will report HRO data on symptom burden and treatment usage to understand symptom variability and HRQoL including those taking iptacopan.

OTHERAtrasentan

Participants and their caregivers will report HRO data on symptom burden and treatment usage to understand symptom variability and HRQoL including those taking atrasentan.